DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic.

Slides:

Advertisements

Similar presentations

Improved FLT3 Internal Tandem Duplication PCR Assay Predicts Outcome after Allogeneic Transplant for Acute Myeloid Leukemia Michael R. Grunwald, Li-Hui.

Advertisements

NPM1, IDH1/2 and DNAH11 Gene Mutations Can Improve a Prognostic Stratification of Acute Myeloid Leukemia Patients with Normal Karyotype but Not Harboring.

Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL.

Highly Variable Pharmacokinetics of Once-Daily Intravenous Busulfan When Combined with Fludarabine in Pediatric Patients: Phase I Clinical Study for Determination.

Serial Measurement of WT1 Expression and Decrement Ratio Until Hematopoietic Cell Transplantation as a Marker of Residual Disease in Patients with Cytogenetically.

Implications and Management of Central Nervous System Involvement before Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia

Influence of GST Gene Polymorphisms on the Clearance of Intravenous Busulfan in Adult Patients Undergoing Hematopoietic Cell Transplantation Sung-Doo.

Changes in Serologic Markers of Hepatitis B Following Autologous Hematopoietic Stem Cell Transplantation Ji Eun Uhm, Kihyun Kim, Tae Kyu Lim, Byeong-Bae.

Improved Outcome of a Reduced Toxicity-Fludarabine, Cyclophosphamide, plus Antithymocyte Globulin Conditioning Regimen for Unrelated Donor Transplantation.

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

Matrix Metalloproteinase-9 in Monocytic Myeloid-Derived Suppressor Cells Correlate with Early Infections and Clinical Outcomes in Allogeneic Hematopoietic.

Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.

Donor-Derived Natural Killer Cells Infused after Human Leukocyte Antigen– Haploidentical Hematopoietic Cell Transplantation: A Dose-Escalation Study Inpyo.

Pre-Engraftment Syndrome after Unrelated Cord Blood Transplantation: A Predictor of Engraftment and Acute Graft-versus-Host Disease Meerim Park, Soo.

Increased Copy Number of the Interleukin-6 Receptor Gene Is Associated with Adverse Survival in Multiple Myeloma Patients Treated with Autologous Stem.

Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched.

Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront.

Hematopoietic Cell Transplantation with and without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1 Andrew M. Brunner,

Incidence and Risk Factors for Early Hepatotoxicity and Its Impact on Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell.

Allogeneic Hematopoietic Stem Cell Transplant for Adults over 40 Years Old with Acquired Aplastic Anemia Hawk Kim, Kyoo-Hyung Lee, Sung-Soo Yoon, Sang.

Comparison of Allogeneic Stem Cell Transplantation from Familial- Mismatched/Haploidentical Donors and from Unrelated Donors in Adults with High-Risk.

Feasible Outcomes of T Cell–Replete Haploidentical Stem Cell Transplantation with Reduced-Intensity Conditioning in Patients with Myelodysplastic Syndrome

CD161+ T Cells as Predictive Markers for Acute Graft-versus-Host Disease Sung-Eun Lee, Ji-Young Lim, Jae-Ho Yoon, Seung-Hwan Shin, Byung-Sik Cho, Ki-Seong.

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Prognostic Factors and Clinical Outcomes of High-Dose Chemotherapy followed by Autologous Stem Cell Transplantation in Patients with Peripheral T Cell.

Highly Variable Pharmacokinetics of Once-Daily Intravenous Busulfan When Combined with Fludarabine in Pediatric Patients: Phase I Clinical Study for Determination.

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility? Jason W. Chien, Keith M. Sullivan Biology.

Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation in Children: Analysis of Prognostic Factors Ji-Man Kang, Yae-Jean Kim,

Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation Gita Thanarajasingam, Haesook T. Kim,

Metal versus plastic stents for drainage of malignant biliary obstruction before primary surgical resection Tae Jun Song, MD, PhD, Jae Hoon Lee, MD,

Graft-versus-Host Disease–Free, Relapse-Free Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Sung-Soo Park, Young-Woo.

Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical.

Monosomal Karyotype Provides Better Prognostic Prediction after Allogeneic Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia Betul.

High-Dose Etoposide Plus Granulocyte Colony-Stimulating Factor as an Effective Chemomobilization Regimen for Autologous Stem Cell Transplantation in Patients.

Stratification of de novo Adult Acute Myelogenous Leukemia with Adverse-Risk Karyotype: Can We Overcome the Worse Prognosis of Adverse-Risk Group Acute.

Successful Prevention of Acute Graft-versus-Host Disease Using Low-Dose Antithymocyte Globulin after Mismatched, Unrelated, Hematopoietic Stem Cell Transplantation.

Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation Vijaya.

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

A Well-Tolerated Regimen of 800 cGy TBI-Fludarabine-Busulfan-ATG for Reliable Engraftment after Unmanipulated Haploidentical Peripheral Blood Stem Cell.

Randomized Comparison of Four-Times-Daily versus Once-Daily Intravenous Busulfan in Conditioning Therapy for Hematopoietic Cell Transplantation Seong-Gil.

Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy.

B Cells and Transplantation: An Educational Resource

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Emerging Importance of Mutational Analysis in Myelodysplastic Syndrome and Acute Myelogenous Leukemia Aaron T. Gerds, Matthew J. Walter, Bart L. Scott

Excellent Outcome of Haploidentical Hematopoietic Stem Cell Transplantation in Children and Adolescents with Acquired Severe Aplastic Anemia Ho Joon.

Diagnostic and Prognostic Value of Mitochondrial DNA Minisatellites after Stem Cell Transplantation Eun Jeong Won, Hye Ran Kim, Hwan Young Kim, Hoon.

Polymorphisms in Genes That Regulate Cyclosporine Metabolism Affect Cyclosporine Blood Levels and Clinical Outcomes in Patients Who Receive Allogeneic.

Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma

Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation Merav Bar, Weigang Tong, Megan Othus,

Participation in Clinical Research: Perspectives of Adult Patients and Parents of Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation

Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated.

Non-CD34+ Cells, Especially CD8+ Cytotoxic T Cells and CD56+ Natural Killer Cells, Rather Than CD34 Cells, Predict Early Engraftment and Better Transplantation.

Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation Ibrahim.

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-

Improving the Informed Consent Process in Hematopoietic Cell Transplantation: Patient, Caregiver, and Provider Perspectives Minakshi Raj, Sung Won Choi,

Blood and Marrow Transplant Handbook

A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation Philippe Armand, Haesook.

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Mammen Chandy Biology of Blood and Marrow Transplantation

Successful Engraftment with Fludarabine, Cyclophosphamide, and Thymoglobulin Conditioning Regimen in Unrelated Transplantation for Severe Aplastic Anemia:

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Treatment versus Transplant for Challenging Hematologic Disorders

Pre-Transplant Comorbidity As an Outcome Predictor in Hematopoietic Cell Transplantation for Severe Aplastic Anemia SungNam Lim, Je-Hwan Lee, MD, PhD,

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Donor-Derived Natural Killer Cell Infusion after Human Leukocyte Antigen– Haploidentical Hematopoietic Cell Transplantation in Patients with Refractory.

Graft-versus-Tumor Effect According to Type of Graft-versus-Host Disease Defined by National Institutes of Health Consensus Criteria and Associated Outcomes

Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic.

Presentation transcript:

DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation Jae-Sook Ahn, Hyeoung-Joon Kim, Yeo-Kyeoung Kim, Seun-Shin Lee, Sung-Hoon Jung, Deok-Hwan Yang, Je-Jung Lee, Nan Young Kim, Seung Hyun Choi, Chul Won Jung, Jun-Ho Jang, Hee Je Kim, Joon Ho Moon, Sang Kyun Sohn, Jong-Ho Won, Sung-Hyun Kim, Dennis Dong Hwan Kim Biology of Blood and Marrow Transplantation Volume 22, Issue 1, Pages 61-70 (January 2016) DOI: 10.1016/j.bbmt.2015.07.030 Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Schematic representation of the mutational status of patients with NK-AML at diagnosis. Colored grids indicate mutation positive. Biology of Blood and Marrow Transplantation 2016 22, 61-70DOI: (10.1016/j.bbmt.2015.07.030) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Prognostic impact on patients with NK-AML after allogeneic HCT. (A) OS, (B) EFS, and (C) RI according to the DNMT3A mutations and their locations. Biology of Blood and Marrow Transplantation 2016 22, 61-70DOI: (10.1016/j.bbmt.2015.07.030) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Prognostic impact on patients with NK-AML after allogeneic HCT. (A) OS, (B) EFS, and (C) RI according to FLT3-ITD and DNMT3A R882 mutational status. Biology of Blood and Marrow Transplantation 2016 22, 61-70DOI: (10.1016/j.bbmt.2015.07.030) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Outcomes of patients undergoing HCT according to FLT3-ITD positivity and DNMT3 R882 mutational status. OS (A, B), EFS (C, D), and RI (E, F), in all patients (A, C, and E), and 1:2 paired patients (B, D, and F) are shown. “Others” includes patients with only FLT3-ITD positivity, a DNMT3A R882 mutation, or wild-type for both. Biology of Blood and Marrow Transplantation 2016 22, 61-70DOI: (10.1016/j.bbmt.2015.07.030) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions